According to the Market Statsville Group (MSG), the global crizotinib market size is expected to grow at a CAGR of 5.4% from 2023 to 2033.
Lung cancer is the cause of one in every five cancer deaths, with "non-small cell lung cancer" being the most common kind of lung cancer worldwide. The government is encouraging health programmers to highlight the dangers of smoking and tobacco use. This will propel the market upward over the next few years. Moreover, crizotinib has shown promising outcomes in cancer indications such as NSLC, prompting suppliers to expand its application to other oncology indications via clinical studies and testing. This has created a lot of opportunities for new and existing players to enter the market and capture the market over the forecasting period all over the world. Further, despite its effectiveness, crizotinib is linked with some adverse effects, which limit the patient's commitment to the treatment and hindered the market growth over the forecasting period.
Crizotinib, also known as Xalkori, is an anti-cancer medicine that is used to treat non-small cell lung carcinoma (NSCLC). It inhibits ALK (anaplastic lymphoma kinase) and ROS1 (c-ros oncogene). Crizotinib is also used to treat certain types of non- small lung cancer cell (NSCLC). It is also used to treat select adults and children 1 year of age and older with anaplastic large cell lymphoma (ALCL) that has returned or is refractory to other treatment(s). Crizotinib is also used to treat adults and children 1 year of age and older with an inflammatory myofibroblastic tumor (IMT; type of cancer that occurs in mucosal tissues usually in the abdominal area, involving the lungs, bladder, stomach, uterus, liver, or intestines) that cannot be treated with surgery or that has not improved or returned after previous treatment.
The COVID-19 began in Wuhan (China) in December 2019 and has since expanded rapidly around the world. In terms of confirmed cases and reported deaths, the United States, India, Brazil, Russia, France, the United Kingdom, Turkey, Italy, and Spain are among the worst impacted nations. Pandemic has also led to disruptions in the supply chain and reduced access to healthcare services in some regions, it has also led to an increased demand for crizotinib in certain areas. The pandemic has led to disruptions in the production and supply of crizotinib, particularly in countries where production facilities have been affected by lockdowns or reduced capacity due to social distancing measures. This has resulted in shortages of crizotinib drug in some regions, which can have serious consequences for people who are suffering from lung disease.
Cancer is a large group of diseases that can start in almost any organ or tissue of the body. Cancer is the second leading cause of death globally, accounting for an estimated 9.6 million deaths, or one in six deaths. According to Cancer.Net Editorial Board, an estimated 236,740 adults (117,910 men and 118,830 women) in the United States will be diagnosed with lung cancer. Worldwide, an estimated 2,206,771 people were diagnosed with lung cancer in 2020. These statistics include both small cell lung cancer and NSCLC. Lung cancer is the leading cause of cancer death for men and women worldwide. It is estimated that 130,180 deaths (68,820 men and 61,360 women) from this disease will occur in the United States. In 2020, an estimated 1,796,144 people died worldwide from the disease. As the cancer disease is increasing day by day in all over the world Crizotinib is the solution that has cured many patients. Due to increasing cancer among the adult and old age this market has registered the growth over the forecasting period.
A side effect is an unwanted symptom caused by medical treatment. All medicines can cause side effects, including prescription, over the counter and complementary medicines. Crizotinib also has some adverse effects on the patient such as Nausea, diarrhea, vomiting, dizziness, tiredness, headache, heartburn, change in taste, loss of appetite, mouth sores, joint pain, trouble sleeping, or constipation may occur. This drug may also cause an increased sensitivity of the skin to sunlight (photosensitivity). This has hindered market growth over the forecasting period all over the world.
ALK inhibitors are anti-cancer drugs that act on tumours with variations of anaplastic lymphoma kinase (ALK) such as an EML4-ALK translocation. There has also been an increase in the demand for treatments combined with therapy, which is pushing treatments with ALK inhibitors, which will have a positive influence on the Crizotinib market. Patient support and reimbursement initiatives will help to reduce drug costs and encourage more patients to get therapy in these centres. There were seen the increase in these centres in all around the world specially in US and Europe. This has created lots of opportunities of this drug over the forecast period.
The study categorizes the crizotinib market based on type, and application area at the regional and global levels.
Based on the type, the market is divided into ALK positive NSCLC and ros1 positive NSCLC. The ALK positive NSCLC segment is expected to dominate the market share in 2022 in the global crizotinib market. The polyvalent segment currently dominates the market share in the crizotinib market. ALK-positive cancer occurs in humans mostly as lung cancer, but it can also originate in many other parts of the body, including brain and breast. ALK-positive lung cancer occurs in approximately 5% of all lung cancer patients. However, it occurs in approximately 30% of lung cancer patients diagnosed under age 40. Unhealthy diet plan and serge in old age people in all around the world has increased the chance of this disease. According to ALK Positive About half of ALK-positive lung cancer patients are diagnosed before the age of 50 (compared to about age 70 for lung cancer overall), with many in their 30’s and 40’s, but some even in their teens and twenties. Due to these reasons this segment has registered the largest market share over the forecasting period.
Based on the regions, the global crizotinib market has been segmented across Europe, North America, the Middle East & Africa, Asia-Pacific, and South America. Asia Pacific is projected to account for the highest market share in 2022 In Asia-Pacific, health warnings against tobacco use, including labels on tobacco product packaging and anti-tobacco mass media campaigns to build public awareness, could be used more to reduce tobacco use. According to OECD, Australia, Pakistan, Singapore, and Thailand report that graphic pictorial warning labels have effectively impacted smoking-related behavior. In addition, the surge in the old age population in this region has also boosted the market growth in this region over the forecasting period.
The crizotinib market is a significant competitor, and extremely cutthroat in the sector are using strategies including product launches, partnerships, acquisitions, agreements, and growth to enhance their market positions. Most sector businesses focus on increasing their operations worldwide and cultivating long-lasting partnerships.
Key Issues Addressed
Frequently Asked Questions
Want to Review Complete Market Research Report
Budget constraints? Get in touch with us for special pricing
Request for Special PricingCustomize this Report
Related Reports
Metagenomics Sequencing Market 2021: Industry Size, Regions, Emerging Trends, Growth Insights, Opportunities, and Forecast By 2027
Mar 2024Medical Cannabis Oil Market 2021: Industry Size, Regions, Emerging Trends, Growth Insights, Development Scenario, Opportunities, and Forecast By 2027
Mar 2024Novel Vaccine Delivery System Market 2021: Industry Size, Regions, Emerging Trends, Growth Insights, Opportunities, and Forecast By 2027
Mar 2024Lysosomal Storage Disease Treatment Market 2021: Industry Size, Regions, Emerging Trends, Growth Insights, Development Scenario, Opportunities, and Forecast By 2027
Mar 2024Single-Use Bioprocessing Market 2022: Industry Size, Emerging Trends, Regions, Growth Insights, Opportunities, and Forecast By 2033
Mar 2024